Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Melanoma 7Prostatic Neoplasms 5Ovarian Neoplasms 5Neoplasm Metastasis 5Recurrence 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Lung Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

Temozolomide 3lutetium Lu 177 dotatate 2Nivolumab 2veliparib 1picropodophyllin 1olaparib 1dostarlimab 1dinutuximab 1cemiplimab 1bempegaldesleukin 1abemaciclib 1Radiotherapy 1Proton Therapy 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Ethanol 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ependymoma × cemiplimab × Clear all
NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡